We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · May 19, 2021

Discontinuing Infliximab in Patients With Ulcerative Colitis in Remission

The Lancet Gastroenterology & Hepatology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Gastroenterology & Hepatology
Discontinuation of Infliximab in Patients With Ulcerative Colitis in Remission (HAYABUSA): A Multicentre, Open-Label, Randomised Controlled Trial
Lancet Gastroenterol Hepatol 2021 Apr 19;[EPub Ahead of Print], T Kobayashi, S Motoya, S Nakamura, T Yamamoto, M Nagahori, S Tanaka, T Hisamatsu, F Hirai, H Nakase, K Watanabe, T Matsumoto, M Tanaka, T Abe, Y Suzuki, M Watanabe, T Hibi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading